Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
CGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $2.95
Previous CloseN/A
Volume950.02K
Average Volume (3M)2.08M
Market Cap
$28.19M
Enterprise Value-$2.49M
Total Cash (Recent Filing)-$2.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.05
Next Earnings
May 07, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding61,972,946
10 Day Avg. Volume699,761
30 Day Avg. Volume2,082,424
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.89
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$5.67Price Target Upside1160.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Drug EffectivenessCognition Therapeutics' CT1812 significantly slows cognitive decline in Alzheimer's patients, highlighting its potential effectiveness.
Market PositionCognition Therapeutics stands out in the Alzheimer's treatment field, especially with recent trial failures from other companies, emphasizing the potential of their CT1812 program.
Trial ExpansionSub-group analyses reaffirm the company's confidence in advancing to a Ph. III study plan, reflecting learnings from the SHINE trial.
Bears Say
Clinical Trial ResultsPatients with p-tau217 above median levels showed similar changes from baseline compared to placebo, with CT1812 treatment being slightly worse than placebo.
Financial PerformanceThe company recorded a net loss of $0.25 per share, wider than forecasted, mainly due to higher-than-anticipated R&D spending.
Regulatory And Market RisksRisks include negative clinical data readouts, inability to advance CT1812 into pivotal trials, and failure to generate favorable top-line data from pivotal trials.
---
Ownership Overview
33.35% Insiders
3.80% Mutual Funds
20.16% Other Institutional Investors
39.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.34 and its highest was $2.95 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $28.19M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Mar 20, 2025. The company reported -$0.189 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.019.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 61,972,946 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.189 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Among the largest hedge funds holding Cognition Therapeutics’s share is Carlson Capital LP. It holds Cognition Therapeutics’s shares valued at 0.
---
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (1160.00% Upside)
$5.67 (1160.00% Upside)
Blogger Sentiment
Bearish
CGTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 140.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.97%
12-Months-Change
Fundamentals
Return on Equity
-157.19%
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
---
CGTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.Read More>---
CGTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(1160.00% Upside)
Technical Analysis
Best Analysts Covering CGTX
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-34.83%
reiterated a buy rating 2 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -34.83% per trade.
---